Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System...

Area of Science:

• Oncology
• Pharmacology
• Health Services Research

Background:

• Advanced prostate cancer treatment is evolving with new therapies.
• Understanding real-world treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) is crucial.
• Optimal treatment sequencing for mCRPC remains an unmet need.

Purpose of the Study:

• To describe real-world treatment patterns and trends in mCRPC in Brazil.
• To identify common first-line, second-line, and third-line therapies for mCRPC.
• To evaluate treatment sequencing in the Brazilian private healthcare system.

Main Methods:

• Retrospective, observational cohort analysis of the Auditron claims database (2014-2019).
• Inclusion of patients with confirmed mCRPC.
• Evaluation of demographics, clinical characteristics, stage at diagnosis, and treatment lines.

Main Results:

• Docetaxel (35.7%), abiraterone (33.3%), and enzalutamide (13.1%) were the most frequent first-line mCRPC treatments.
• These agents also dominated second-line (docetaxel 34.6%, abiraterone 28.0%, enzalutamide 15.0%) and third-line therapies (cabazitaxel 26.1%, enzalutamide 23.9%, docetaxel 15.2%, abiraterone 15.2%).
• Treatment patterns were consistent regardless of initial prostate cancer stage upon progression to mCRPC.

Conclusions:

• Docetaxel, abiraterone, and enzalutamide are the most utilized therapies for mCRPC in Brazil.
• The study provides real-world insights into mCRPC treatment patterns in Brazil.
• Further real-world data are necessary to validate and expand these findings.